<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1592">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02033200</url>
  </required_header>
  <id_info>
    <org_study_id>TA-402</org_study_id>
    <nct_id>NCT02033200</nct_id>
  </id_info>
  <brief_title>Safety Study Looking at the Effects of Stendra on Vision</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Single-Dose, Parallel Study to Assess the Effects of Avanafil (STENDRA™) on Multiple Parameters of Vision, Including, But Not Limited to Visual Acuity, Intraocular Pressure, Pupillometry, and Color Vision Discrimination, in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VIVUS, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VIVUS, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if Stendra causes any changes in vision, eye pressure,
      pupil dilation, and color vision in healthy males.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of this study are to assess the effect of Stendra on visual acuity,
      intraocular pressure, pupillometry, and color vision discrimination in healthy male
      subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Effect of Stendra 1 hour post dosing on color vision discrimination</measure>
    <time_frame>1 hour</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Stendra 1 hour post dosing on visual acuity</measure>
    <time_frame>1 hour</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Stendra 1 hour post dosing pupil dilation</measure>
    <time_frame>1 hour</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Stendra 1 hour post dosing on Intraocular pressure</measure>
    <time_frame>1 hour</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of Stendra 24 hours post dosing on visual acuity</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Stendra 24 hour post dosing on pupil dilation</measure>
    <time_frame>24 hour</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Stendra 24 hour post dosing on color vision discrimination</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Stendra 24 hour post dosing on intraocular pressure</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Vision</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stendra 200 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stendra 200 mg</intervention_name>
    <arm_group_label>Active</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>avanafil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Active</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult males 18 to 45 years of age, inclusive

          -  Non-tobacco user for at least 6 months prior to first dose

        Exclusion Criteria:

          -  History or presence of retinal disease or any vision defects including color vision

          -  Intraocular pressure value ≥ 22mm Hg

          -  Resting heart rate &lt; 45 or &gt; 90 beats per minute (3 rechecks)

          -  Systolic blood pressure &lt; 90 or &gt; 140 mm Hg or Diastolic blood pressure &lt; 50 or &gt;90
             mm Hg (3 rechecks)

          -  Initiation or change in dose of any α-blockers 14 days prior to randomization
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Celerion Inc</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 18, 2014</lastchanged_date>
  <firstreceived_date>January 8, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vision</keyword>
  <keyword>Stendra</keyword>
  <keyword>avanafil</keyword>
  <keyword>PDE5 inhibitor</keyword>
  <keyword>visual acuity</keyword>
  <keyword>intraocular pressure</keyword>
  <keyword>pupillometry</keyword>
  <keyword>color vision discrimination</keyword>
  <keyword>healthy males</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
